The incidence and outcomes of high-risk acute coronary syndromes in Western Cape Province, South Africa: A prospective cohort study

J D Cilliers,1 MB ChB; L Joubert,1 MMed (Int); M Philips,2 MB ChB; B Beyers,1 MB ChB; E Ngarande,2 BSc Hons (Medical Biochemistry), PhD; P Herbst,2 MB ChB, MMed (Int); A Doubell,2 MMed (Int), PhD; A Pecoraro,4 MMed (Int), PhD

1 Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, and Tygerberg Hospital, Cape Town, South Africa
2 Division of Cardiology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, and Tygerberg Hospital, Cape Town, South Africa

Corresponding author: J D Cilliers (jdcilliers123@gmail.com)

Background. Tygerberg Hospital (TBH) is a tertiary-level hospital in Western Cape Province, South Africa, that provides healthcare to a large low- to middle-income population with services including centralised advanced cardiac care. Acute coronary syndrome (ACS) remains an important cause of death in the region despite a high burden of communicable diseases, including HIV.

Objectives. To describe the incidence of ST-elevation myocardial infarction (STEMI) and high-risk non-ST-elevation ACS (HR-NSTEACS) in the TBH referral network, describe the in-hospital and 30-day mortality of these patients, and identify important high-risk population characteristics.

Methods. The Tygerberg Acute Coronary Syndrome Registry database is an ongoing prospective study that enrols all STEMI and HR-NSTEACS patients in the TBH referral network. All patients aged >18 years presenting with STEMI or HR-NSTEACS were treated in accordance with current European Society of Cardiology guidelines and were included prospectively over a 9-month surveillance period. A waiver of consent was granted to include patients who died before giving informed consent. Data collected included a demographic profile, risk factors for cardiovascular disease, in-hospital therapy and 30-day mortality.

Results. A total of 586 patients were enrolled, with a male predominance (64.5%) and incidence rates of STEMI and HR-NSTEACS of 14.7 per 100 000 and 15.6 per 100 000, respectively. The mean patient age was 58 years, and STEMI patients tended to be younger than HR-NSTEACS patients (56 v. 58 years; p=0.01). Cardiovascular risk factors were prevalent overall, but hypertension (79.8% v. 68.3%; p<0.01) and pre-existing IHD (29.1% v. 7.0%; p=0.03) were more prevalent in the HR-NSTEACS group. HIV was present in 12.6% of patients tested, similar to the background population rate. The overall 30-day all-cause mortality rate was 6.1%, with an in-hospital mortality rate of 3.9%. The 30-day mortality rates were similar for STEMI (1.8%) and HR-NSTEACS (2.6%) (p=0.75). HIV did not affect mortality rates.

Conclusion. Use of a guideline-based approach to treating ACS in a low- to middle-income country setting yields mortality rates comparable to those in high-income countries. However, the lower-than-expected incidence rates of both STEMI and HR-NSTEACS in a relatively young population with a high prevalence of traditional cardiovascular risk factors, and a relatively high proportion of STEMIs, suggest potential under-recording of ischaemic heart disease in the region. The rate and outcomes of coronary artery disease (CAD) in people living with HIV were similar to those in people without HIV, suggesting that traditional risk factors still drive CAD outcomes in the region.


Cardiovascular disease (CVD) is the leading cause of death worldwide.[1] Despite a high burden of communicable disease, ischaemic heart disease (IHD) is the 10th most common cause of death in South Africa (SA), and recent data suggest that it is on the rise.[2] IHD was ranked as the most common cause of death in a recent survey in Western Cape Province, at 90 per 100 000.[3] SA is an upper-middle-income country (UMIC) as defined by the 2021 World Bank summary.[4] However, although SA is an UMIC, because of inequality in resource distribution a large proportion of its population face challenges characteristic of a low- to middle-income country (LMIC).[5]

Acute coronary syndrome (ACS), particularly ST-elevation myocardial infarction (STEMI) and high-risk non-ST-elevation ACS (HR-NSTEACS), is a major contributor to the mortality associated with IHD. Prospective registries from high-income countries in Europe (Euro Heart Survey)[5] and the USA (GRACE survey)[6] report in-hospital mortality rates for STEMI of 7% and 8%, respectively, with lower in-hospital mortality rates reported for non-ST elevation ACS (NSTEACS) (2.4% and 5%). The Euro Heart Survey reported 30-day mortality rates of 8.5% for STEMI and 3.5% for NSTEACS.[5,6] It should be noted that the NSTEACS groups in these studies were not limited to HR-NSTEACS patients. The outcomes of ACS have not been prospectively studied in SA, and the only available information comes from death notifications reported by the SA statistical services.[2]

European registries suggest a STEMI incidence of 50 - 60 per 100 000 patient-years of the population, with the incidence of HR-NSTEACS being almost double that of STEMI.[1,2] Data from our own unit suggest that STEMI is less common than reported in these high-income countries,[6] with no data available on the incidence of HR-NSTEACS in SA.[6] Whether this finding reflects a truly lower incidence of the condition or under-reporting and/or undertreatment of the population remains unknown. A prevalence
of traditional risk factors for CVD similar to that in high-income countries has been reported in SA,\(^8\) although the specific risk factor profile of the ACS population in SA remains unknown.\(^9\) The prevalence of HIV, a possible additional risk factor for premature coronary artery disease (CAD) and ACS, is close to 10% in the Western Cape, with a treatment rate of ~30%.\(^9\) A recent study from our institution reported an HIV prevalence of 3.4% in patients presenting with ACS.\(^9\)

Protocolised management of ACS, and in particular patients with STEMI, has been shown to improve patient outcomes.\(^6,10\) All patients in the Tygerberg Hospital (TBH) referral network presenting with STEMI and HR-NSTEACS are referred to TBH for definitive care, ultimately resulting in protocolised management of patients presenting with ACS, in keeping with current European Society of Cardiology (ESC) guidelines, throughout the region.\(^11\)

Our objective was to describe the incidence, mortality rates and cardiovascular risk factor profile of patients presenting with STEMI and HR-NSTEACS in the TBH referral network and compare these with published cohorts.

Methods
The Tygerberg Acute Coronary Syndrome Registry is an ongoing prospective cohort study of patients with HR-NSTEACS and STEMI presenting to healthcare facilities in the TBH referral network. The Division of Cardiology at TBH, Cape Town, is a public sector tertiary referral centre that serves a population of ~2.4 million people. All patients with STEMI/HR-NSTEACS presenting to healthcare facilities in our referral network are referred to TBH for definitive care.\(^10\)

All patients aged >18 years diagnosed with either STEMI or HR-NSTEACS were included in this prospective study for the period July 2020 - March 2021. A waiver of consent was granted to include patients who died before giving informed consent.

STEMI and HR-NSTEACS were defined using established definitions as outlined by current guidelines.\(^11\) A STEMI diagnosis required patients to present with typical chest pain consistent with myocardial ischaemia, associated with ST-segment elevation in two contiguous leads of at least 1 mm on an electrocardiogram (ECG).\(^12,13\) HR-NSTEACS was diagnosed in patients presenting with typical chest pain consistent with myocardial ischaemia without ST elevation, but with one of the following high-risk features: ongoing chest pain, haemodynamic or electrical instability, dynamic ST- or T-wave changes on the ECG, mainstem pattern on the ECG, ECG suggestive of a left anterior descending artery syndrome, or elevated troponin T level, TIMI score or Grace score, per the ESC guidelines.\(^11,12\) All patients were managed by a cardiologist and the diagnosis was independently verified by the study investigators. Prospective data collected included baseline demographic profile, risk factors for CVD, and in-hospital treatment outcome in terms of survival. All patients were offered guideline-directed therapy including coronary angiography with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) as indicated.\(^2,7\) Patients were contacted telephonically a month after discharge to confirm survival, evaluate their symptoms and assess compliance with medication.

In terms of treatment of patients with STEMI, a pharmaco-invasive strategy is followed. Patients receive fibrinolysis at their presenting hospital (spoke), provided no contraindication is present, followed by referral to TBH (hub) for angiography and consideration for PCI.\(^6\) All patients with HR-NSTEACS are transferred to the hub for angiography and further intervention. A forced referral pathway is therefore in place to ensure that all patients in our geographical service area who present with STEMI and HR-NSTEACS are referred to TBH. The SUNHEART Cardiology Outreach Programme, established in 2013, created a hub-and-spoke model to deliver cardiovascular care in the TBH referral network in the Western Cape.\(^12\)

Statistical analysis
Data were analysed using using SPSS Statistics version 27 (IBM Corp., USA). Data are expressed as means with standard deviations, medians with interquartile ranges and numbers with percentages, according to the order of the variables and distribution of data. Categorical variables were compared using cross-tabulation and the \(\chi^2\) test. Comparisons between groups with normal distributions were performed using Student's \(t\)-test. Groups that were not normally distributed were compared using the Mann-Whitney \(U\)-test. A p-value of <0.05 was used to ascribe statistical significance.

The most recent census data report the population living within the TBH referral network to be 3 million.\(^14\) Approximately 20% of this population has access to private healthcare, so the population used to calculate incidence rates was 2.4 million.\(^14\)

Ethics approval
The study was approved by the Health Research Ethics Committee of the Faculty of Medicine and Health Sciences, Stellenbosch University (ref. no. N20/03/030), and performed in accordance with the Declaration of Helsinki (2013 version). All patients signed written informed consent. A waiver of consent was granted to include patients who died before being able to give informed consent.

Results
A total of 586 patients were enrolled over the 9-month study period (Fig. 1), with a male predominance (64.5%) and incidence rates for STEMI and HR-NSTEACS of 14.7 per 100 000 and 15.6 per 100 000, respectively (Table 1). The mean patient age was 58 years, with STEMI patients younger than HR-NSTEACS patients (56 v. 58 years; \(p=0.01\)).

The prevalences of the major cardiovascular risk factors diabetes mellitus, dyslipidaemia and smoking were similar in the two groups (Table 1). However, hypertension (79.8% v. 68.3%; \(p<0.01\)) and pre-existing IHD (29.1% v.7.0%; \(p=0.03\)) were significantly more prevalent in the HR-NSTEACS group.

HIV status was available for 183 patients (31.2%), with 12.6% of these patients being HIV positive. Nearly three-quarters of the patients in this cohort were on antiretroviral therapy, none of whom received protease inhibitors. People living with HIV (PLHIV) in this study were younger than

---

**Fig. 1. The study population.**
those who were HIV negative (47 v. 58 years; \(p<0.01\)) and were more likely to present with a STEMI than with HR-NSTEACS (73.9% v. 26.1%; \(p<0.01\)), although their major cardiovascular risk profile was similar to that of HIV-negative patients (Table 2).

A total of 23 patients died in hospital, and a further 13 within 30 days of diagnosis. The all-cause mortality rate was 6.1% (\(n=36/586\)) at 30 days post admission, with an in-hospital mortality rate of 3.9% (\(n=23/586\)) and an out-of-hospital mortality rate of 2.2% (\(n=13/586\)) (Table 3). The in-hospital and out-of-hospital mortality rates were similar for the STEMI and HR-NSTEACS patients (Table 3).

The majority of patients underwent coronary angiography (\(n=571/586\); 97.4%) (Table 4). Of these, 434 (76.0%) underwent revascularisation procedures, with the majority undergoing PCI (\(n=364\); 63.7%) and 70 (12.3%) undergoing CABG. A relatively high proportion of patients (\(n=57/302\); 18.9%) in the HR-NSTEACS group met the criteria for emergency angiography (5 of these patients had haemodynamic instability and 52 ongoing chest pain). Not having

### Table 1. Demographics and cardiovascular risk profile of the study population

<table>
<thead>
<tr>
<th>Variable</th>
<th>All patients ((N=586), (n) (%)*</th>
<th>STEMI ((n=284), (n) (%)*</th>
<th>HR-NSTEACS ((n=302), (n) (%)*</th>
<th>(p)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>58 (11.5)</td>
<td>56 (11.4)</td>
<td>58 (11.5)</td>
<td>0.01</td>
</tr>
<tr>
<td>Male gender</td>
<td>378 (64.5)</td>
<td>182 (64.1)</td>
<td>196 (64.9)</td>
<td>0.39</td>
</tr>
<tr>
<td>CVRF profile</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>436 (74.4)</td>
<td>194 (68.3)</td>
<td>241 (79.8)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>217 (37.0)</td>
<td>93 (32.7)</td>
<td>124 (41.1)</td>
<td>0.61</td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td>405 (69.1)</td>
<td>207 (72.9)</td>
<td>198 (65.6)</td>
<td>0.13</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>87 (14.8)</td>
<td>40 (14.1)</td>
<td>47 (15.6)</td>
<td>0.25</td>
</tr>
<tr>
<td>Family history of premature CAD</td>
<td>19 (3.2)</td>
<td>9 (3.2)</td>
<td>10 (3.3)</td>
<td>0.93</td>
</tr>
<tr>
<td>Pre-existing IHD</td>
<td>108 (18.4)</td>
<td>20 (7.0)</td>
<td>88 (29.1)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

STEMI = ST-elevation myocardial infarct; HR-NSTEACS = high-risk non-ST-elevation acute coronary syndrome; SD = standard deviation; CVRF = cardiovascular risk factor; CAD = coronary artery disease; IHD = ischaemic heart disease.

*Except where otherwise indicated.

### Table 2. Patients with known HIV status

<table>
<thead>
<tr>
<th>Variable</th>
<th>HIV positive ((n=23), (n) (%)*</th>
<th>HIV negative ((n=160), (n) (%)*</th>
<th>(p)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>On cART</td>
<td>17 (73.9)</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>17 (73.9)</td>
<td>68 (42.5)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HR-NSTEACS</td>
<td>6 (26.1)</td>
<td>92 (57.5)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Age (years), mean</td>
<td>47</td>
<td>58</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Smoking</td>
<td>14 (60.8)</td>
<td>113 (70.6)</td>
<td>0.32</td>
</tr>
<tr>
<td>Hypertension</td>
<td>18 (78.2)</td>
<td>114 (71.3)</td>
<td>0.48</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>8 (34.7)</td>
<td>59 (36.8)</td>
<td>0.84</td>
</tr>
<tr>
<td>LDL &gt;4 mmol/L</td>
<td>2 (8.7)</td>
<td>28 (17.5)</td>
<td>0.83</td>
</tr>
<tr>
<td>Mortality STEMI</td>
<td>0</td>
<td>9 (5.6)</td>
<td>0.34</td>
</tr>
<tr>
<td>Mortality HR-NSTEACS</td>
<td>0</td>
<td>6 (3.8)</td>
<td>0.24</td>
</tr>
</tbody>
</table>

cART = combination antiretroviral therapy; n/a = not applicable; STEMI = ST-elevation myocardial infarct; HR-NSTEACS = high-risk non-ST-elevation acute coronary syndrome; LDL = low-density lipoprotein.

*Except where otherwise indicated.

### Table 3. Mortality

<table>
<thead>
<tr>
<th>Variable</th>
<th>All patients ((N=586), (n) (%))</th>
<th>STEMI ((n=284), (n) (%))</th>
<th>HR-NSTEACS ((n=302), (n) (%))</th>
<th>(p)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In hospital</td>
<td>23 (3.9)</td>
<td>14 (4.9)</td>
<td>9 (3.0)</td>
<td>0.46</td>
</tr>
<tr>
<td>Within 30 days</td>
<td>13 (2.2)</td>
<td>5 (1.8)</td>
<td>8 (2.6)</td>
<td>0.75</td>
</tr>
</tbody>
</table>

STEMI = ST-elevation myocardial infarct; HR-NSTEACS = high-risk non-ST-elevation acute coronary syndrome.

### Table 4. Interventional strategy

<table>
<thead>
<tr>
<th>Variable</th>
<th>All patients ((N=586), (n) (%))</th>
<th>STEMI ((n=284), (n) (%))</th>
<th>HR-NSTEACS ((n=302), (n) (%))</th>
<th>(p)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiogram</td>
<td>571 (97.4)</td>
<td>273 (96.1)</td>
<td>298 (98.7)</td>
<td>0.35</td>
</tr>
<tr>
<td>No intervention</td>
<td>137 (24.0)</td>
<td>31 (11.4)</td>
<td>106 (35.6)</td>
<td>0.53</td>
</tr>
<tr>
<td>PCI</td>
<td>364 (63.7)</td>
<td>224 (82.1)</td>
<td>140 (47.0)</td>
<td>0.03</td>
</tr>
<tr>
<td>CABG</td>
<td>70 (12.3)</td>
<td>18 (6.6)</td>
<td>52 (17.4)</td>
<td>0.74</td>
</tr>
</tbody>
</table>

STEMI = ST-elevation myocardial infarct; HR-NSTEACS = high-risk non-ST-elevation acute coronary syndrome; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting.
an angiogram was the only statistically significant factor influencing poor outcome (p < 0.01). PCI was more frequently performed in STEMI patients than in those with HR-NSTEACS, with similar CABG rates across the groups (Table 4). Of the 15 patients who did not undergo angiography, 9 died before the intervention could be performed and 2 had severe renal failure.

COVID-19 status was available for 372/386 patients, with only 3.1% having a positive polymerase chain reaction (PCR) test. COVID-19 status did not influence the presenting diagnosis, with an equal distribution between STEMI and HR-NSTEACS (p = 0.984). One patient with COVID-19 died within 30 days of admission, but there was no association between COVID-19 PCR positivity and 30-day mortality (p = 0.81).

**Discussion**

This study demonstrates that the use of a contemporary guideline-based approach to treating ACS in an LMIC setting, as practised in our institution, can yield mortality rates comparable to outcomes from high-income countries. However, the lower-than-expected incidence rates of both STEMI and NSTEACS in a relatively young population with a high prevalence of traditional CAD risk factors, and a relatively high proportion of STEMI in the population, suggest potential under-recording of IHD in the region. The rate and outcomes of CAD in PLHIV were similar to those in HIV-negative people. However, PLHIV presented at a younger age with predominantly STEMI.

Similar in-hospital (4.9% v. 3.0%; p = 0.46) and 30-day mortality rates (1.8% and 2.6%; p = 0.75) for patients presenting with STEMI and HR-NSTEACS were observed, with the mortality rate in the STEMI group similar to published cohorts utilising a pharmacoinvasive strategy. NSTEACS is traditionally associated with lower in-hospital and 30-day mortality compared with STEMI. Our cohort only included the high-risk subgroup of NSTEACS patients, which may account for the similar mortality in the two groups. This finding is further supported by the similarity of our mortality data to reported mortality rates for HR-NSTEACS. Mortality rates for both STEMI and NSTEACS have decreased with advances in medical therapy and improved access to angiography and revascularisation.

Access to healthcare services, in particular timeous angiography and PCI in the setting of ACS, is an important determinant of outcome. The availability of these services varies among countries, with high-income countries having easier and more equal access to angiography and PCI.

The paucity of data from SA and Africa makes comparison with previously published data difficult. Previous data from our unit reported a 30-day mortality rate of 6.4% for STEMI patients, while data from the SA private sector, which is considerably better resourced, showed a 30-day mortality rate of 4.1%. Other studies from resource-limited countries in Africa, where access to healthcare, specifically angiography and PCI, may be more limited, have reported significantly higher mortality rates ranging from 22% to 28%. The majority of patients in our cohort underwent angiography with subsequent revascularisation (as per guideline indication), despite the typical constraints associated with cardiovascular care in the public healthcare sector in SA. The ability to provide this service was made possible by centralising regional care in a hub-and-spoke model with a protocolised treatment approach to ACS. Angiography with subsequent PCI or CABG is well established as an important strategy to lower the mortality and morbidity associated with both STEMI and HR-NSTEACS. The high rate of access to angiography and subsequent revascularisation in our cohort is likely to have contributed to the lower-than-expected mortality rate (similar to developed-world cohorts) observed.

The prevalence of the major cardiovascular risk factors, including hypertension, diabetes mellitus and dyslipidaemia, was comparable to that in patients in other registries in the developed world as well as retrospective data from sub-Saharan Africa. However, smoking was more prevalent in our population (69.1%) compared with developed-world cohorts (40 - 50%) and other cohorts from sub-Saharan Africa (20%). Systemic hypertension was more prevalent in the HR-NSTEACS population than in the STEMI population (79.8% v. 68.3%; p < 0.01), possibly owing to the more advanced age of the HR-NSTEACS population. Overall, our cohort of patients was younger, with a mean age of 58 years, compared with developed-world cohorts, which report a mean age of 65 - 68 years.

In PLHIV, the incidence of STEMI was significantly higher than that of HR-NSTEACS (73.9% v. 26.1%; p = 0.05), and patients with STEMI were younger at presentation (Table 3). Although we did not detect a difference in risk factor profile, the younger age of presentation with predominantly STEMI may be due to the chronic inflammation associated with HIV infection, but this finding requires further investigation.

We found the incidence of STEMI and HR-NSTEACS to be 14.7 and 15.6 per 100 000, respectively, amounting to a total of 30.3 events per 100 000 patient-years. This figure is considerably lower than the incidence reported from high-income countries, where the incidence of STEMI is reported as 40 - 60 per 100 000, and that of NSTEACS as 80 - 120 per 100 000.

A number of factors should be considered as explanations for the lower-than-expected incidence observed. The average age of our patient cohort is lower than in developed countries. However, despite this younger population, the prevalence of traditional risk factors for IHD is similar to that in developed countries. For this reason, a truly lower incidence of atherosclerotic disease and ACS in SA is unlikely. A decline in the incidence of ACS in cohorts from high-income countries over the past 2 - 3 decades has been associated with a greater decrease in the proportion of STEMI compared with NSTEACS. The STEMI-to-NSTEACS ratio has therefore been suggested as an important barometer of where along the IHD burden curve a population finds itself. The relatively high rate of STEMI in the present study lends further support to the idea of under-reporting rather than a true lower incidence of the disease. The lower incidence is probably at least in part explained by referral bias. Only patients referred to our facility were included, and poor health-seeking behaviour, under-detection of ACS at referral facilities, pre-referral mortality and inappropriate discharge of patients diagnosed with ACS may therefore have affected the size of the cohort. While it could be argued that the developed-world cohorts are subject to similar biases, the attrition rate may be higher in our cohort owing to the resource-limited nature of our healthcare system.

An additional explanation for the lower incidence may be the SARS-CoV-2 pandemic, which coincided with our enrolment period. Local and international data indicated a decline in the number of ACS admissions during the pandemic, and this may be a significant contributor to the lower incidence observed.

**Study limitations**

Although a protocolised referral system is employed in our referral network, we only captured data from the patients who were referred
to our hospital, and this study is therefore limited by the usual factors associated with referral bias.

The study took place during the COVID-19 pandemic. During this period the incidence of both STEMI and NSTEACS were lower than normal. It is not possible to quantify the impact of the COVID-pandemic on all-cause mortality reported in this study.

**Conclusions**

The use of a contemporary, guideline-based approach to treating ACS in an LMIC setting yields mortality rates comparable to those in high-income countries. However, the lower-than-expected incidence rates of both STEMI and NSTEACS in a relatively young population with a high prevalence of traditional CAD risk factors, and a relatively high proportion of STEMI, suggest potential under-recording of IHD in an LMIC setting.


**Declaration**

The research for this study was done in partial fulfilment of the requirements for JDC's MMed (Internal Medicine) degree at Stellenbosch University.

**Acknowledgements.** None.

**Author contributions.** JDC: investigation, writing original draft. LJ: conceptualisation, formal analysis, reviewing and editing. AP: conceptualisation, methodology, reviewing and editing. AD: conceptualisation, methodology, reviewing and editing. PH: reviewing and editing. EN: data capture, reviewing and editing. BB: reviewing and editing.

**Funding.** None.

**Conflicts of interest.** None.

---


